I've noticed that my numbers still go up and down while I have been on Soliris. I have been getting treatments with it since February 2013 till the present time. The one that I notice the most is the platelets. For example, two weeks ago my platelets were 164 and this week they are 136. I know this isn't horrible (especially after seeing them way lower than this a year ago), but it makes me wonder if or when Soliris will start kicking in. Anyone having the same situation? Please comment…Continue
As many of you know, Nathan had wonderful results with his kidney/soliris transplant. What you might not have known was his schooling was suffering a bit and he had some motor skill issues and endurance/strength problems. He has been working with physical therapists, speech therapist and occupatiinal therapists for the last six months to address lingering problems.
Physical therapy went extremely well, especially after they diagnosed a curvature at his ankles and he was fitted with…Continue
I am 28 years old and have been recently diagnosed with aHUS. Back in March 7, 2013, I went into the hospital with what I thought was a ruptured gall baller. I had been sick for almost a week with flu symptoms. I went to my local doctor because I thought he could give me some Tamaflu before I went on a small vacation with my husband to Columbus, Ohio. My doctor took one look at me and decided that I had to go to the hospital and referred me to a doctor at Flower Hospital in Sylvania, Ohio.…Continue
On September 23, 2011, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the use of eculizumab (Soliris®, product of Alexion Pharmaceuticals, Inc.) for the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS). Two phase 2 trials were conducted and researchers found that long-term treatment with eculizumab (Soliris®) was highly effective in ‘thwarting thrombotic…
Added by Linda Burke on June 7, 2013 at 12:21am — No Comments
On May 28, 2013 Omeros Corporation announced its filing of a Clinical Trial Application (CTA) with European regulators to initiate clinical trials evaluating OMS721, the company's lead human monoclonal antibody. This follows their April 2013 application for OMS721 to receive Orphan Drug Designation with the US Food and Drug Administration (FDA).
The lead indication for OMS721 will be atypical hemolytic uremic syndrome or aHUS. Assuming positive regulatory review of its CTA,…Continue